The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4.
The Personalized Medicine Based on Molecular Profiling of Patients with Cancer implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.
The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4.
This document is the Use of Sequencing to Guide the Care of Cancer Patients study protocol.
This document is the study protocol of the Institutional and Professional Impact of Genomic Sequencing in Cancer Care study.
This published study protocol for the MedSeq trials includes a description of the study design; recruitment, enrollment, and sample size plan; patient exclusion/inclusion criteria; and process of interpreting WGS results and delivering them to physicians. It also includes an example of a general genome report as well as a cardiac risk report.